Home Tags Clinical trials
Tag: clinical trials
Pure Transplant Solutions Announces Collaboration with King’s College London to Support NHS Funded GAMECHANgER-1 Clinical Trial for HLA Sensitized Patients with...
AUSTIN, Texas and LONDON, England, Feb. 24, 2021 (SEND2PRESS NEWSWIRE) -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with King's College London.
Kalyagen™ Announces Launch of Clinical Trial to Evaluate STEMREGEN® and Stem Cells for Advanced Heart Failure Patients
AUSTIN, Texas, Feb. 5, 2021 (SEND2PRESS NEWSWIRE) -- Kalyagen™, along with the Sociedad Espanola de Medicina Regenerativa y Terapia Celular (the "Spanish Society of Regenerative Medicine and Cell Therapy"), is pleased to announce the launch of a multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure.
NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor
CAMBRIDGE, Mass., Oct. 6, 2020 (SEND2PRESS NEWSWIRE) -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease.
PARK CITY, Utah, May 26, 2020 (SEND2PRESS NEWSWIRE) -- Silent Hypoxia is a frequent disabling and sometimes fatal complication in COVID-19 disease. To prevent SARS-CoV-2 coronavirus-induced damage to patients' lungs and Silent Hypoxia in patients, Aristea Translational Medicine Corp. has initiated development of PhenT, a drug with novel cellular protective properties.
ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2...
LOS ANGELES, Calif., April 2, 2020 (SEND2PRESS NEWSWIRE) -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.
iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting
STONY BROOK, N.Y., Nov. 14, 2019 (SEND@PRESS NEWSWIRE) -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.